ProSharesInverse EquityBIS · Nasdaq

ProShares UltraShort Nasdaq Biotechnology (BIS)

Compare Leveraged & Inverse ETFs Compare with others

Price: $11.26; —25 Sept 2026
Assets: $1.9M; Total net assets
Expense ratio: 0.95%; Category 0.00%
Yield: 6.96%; Trailing distributions

1Y return: -58.4%-24.8%; Category -33.6%
3Y CAGR: -34.6%+0.5%; Category -35.1%
5Y CAGR: -17.6%+7.9%; Category -25.4%

Loading NAV history…

ProShares UltraShort Nasdaq Biotechnology

Calendar-year returns

Fund only: no comparison series covers this fund's history.

Risk statistics

Five years of daily closes. Risk-free rate 4% a year.

Standard deviation: —
Maximum drawdown: —
Sharpe ratio: —
Sortino ratio: —
Beta: —
Alpha: —
R²: —
Information ratio: —
Upside capture: —
Downside capture: —
Tracking error: —

Trailing returns compared with benchmark
Period	1M	3M	6M	YTD	1Y	3YCAGR	5YCAGR	10YCAGR	LaunchCAGR
ETF	+7.1%	-18.3%	-41.4%	-38.9%	-58.4%	-34.6%	-17.6%	-25.3%	-33.1%
Inverse Equity average	-6.2%	-18.4%	-38.8%	-34.4%	-33.6%	-35.1%	-25.4%	-29.6%	-41.7%
Difference	+13.3%	+0.1%	-2.6%	-4.5%	-24.8%	+0.5%	+7.9%	+4.4%	+8.7%

Holdings

Allocation as last published by the fund.

Asset mix

What the fund is invested in.

Cash199.9%
Other100.0%

ETF details

Issuer: ProShares
Category: Equity · Inverse Equity
Ticker: BIS
Exchange: Nasdaq
Inception: 6 Apr 2010 (16.5 years)
Structure: Exchange Traded Fund
Expense ratio: 0.95% (category 0.00%)
Holdings turnover: 0%
Distribution yield: 6.96%
Beta, 3 years: -1.21
Total net assets: $1.9M

Prices and returns as of 25 Sept 2026; total return with distributions reinvested, before brokerage and taxes. Not investment advice.

Other inverse equity ETFs

Other ETFs in the Inverse Equity category.

Compare Leveraged & Inverse ETFs